Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9241163 | 1.00 | HTR2A (0.44) | HTR2AACP3RETTSHRNPSR1 | |
| SCHEMBL9242330 | 1.00 | HTR2A (0.44) | HTR2AACP3RETTSHRNPSR1 | |
| Hydrochloric Acid SCHEMBL9249933 | 0.98 | TSHR (0.45) | HTR2AACP3RETTSHRNPSR1 | |
| Hydrochloric Acid SCHEMBL9241955 | 0.98 | TSHR (0.45) | HTR2AACP3RETTSHRNPSR1 | |
| Hydrochloric Acid SCHEMBL9240266 | 0.98 | TSHR (0.45) | HTR2AACP3RETTSHRNPSR1 | |
| SCHEMBL9244027 | 0.85 | MTNR1B (0.38) | HTR2AACP3TSHRNPSR1HTT | |
| SCHEMBL10739890 | 0.81 | ACP3 (0.47) | HTR2AACP3RETTSHRNPSR1 | |
| SCHEMBL7681625 | 0.79 | CYP1A2 (0.56) | TSHRGRM1GRM2GRM4CYP1A2 | |
| SCHEMBL8197048 | 0.79 | CYP1A2 (0.56) | TSHRGRM1GRM2GRM4CYP1A2 | |
| SCHEMBL31609333 | 0.79 | IDO1 (0.42) | TSHRNPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0637305-A1 | NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1995-02-08 | — | — | EP | claimed |
| WO-1993021176-A1 | NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-10-28 | — | — | WO | claimed |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| EP-2620436-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO (JP) | 2018-05-09 | — | — | EP | disclosed |
| EP-2444400-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9815835-B2 | Substituted polycyclic carbamolypyridone derivative | SHIONOGI & CO., LTD. (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9815835-B2 | Substituted polycyclic carbamolypyridone derivative | SHIONOGI & CO., LTD. (JP) | 2017-11-14 | — | — | US | disclosed |
| US-6096744-A | ANTICONVULSANTS | WARNER-LAMBERT COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| US-6063774-A | NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1998027097-A1 | TRICYCLIC QUINOXALINE DERIVATIVES AS NEUROPROTECTIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| US-5614508-A | ANTIISCHEMIC AGENTS, ALZHEIMERS, STROKE OR NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| US-5449778-A | Peptide intermediates | WARNER-LAMBERT COMPANY (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0637305-A1 | NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5380925-A | Cyclic amino acids and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| US-5264577-A | Cyclic amino acids and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1993021176-A1 | NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885ACP3 773/4885RET 2798/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885ACP3 773/4885RET 2798/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | HTR2A 3231/4885ACP3 782/4885RET 2683/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | HTR2A 3244/4885ACP3 773/4885RET 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.